[Edaily Reporter Kwon Oh Seok ] #Xcell Therapeutics Inc.’s stock price is surging in early trading. It appears that buying interest is surging on the back of positive outlooks from the securities industry.

According to MP Doctor on the 7th, Xcell Therapeutics Inc. is trading at 1,370 won as of 9:29 a.m., up 10.22% from the previous trading day.
Earlier today, the independent research firm Value Finder released a report on Xcell Therapeutics Inc., stating, “Cumulative sales for the first half of the year have increased more than fivefold compared to the same period last year, indicating the company has entered a growth cycle.” The report also noted that the company’s cell culture medium is being applied to MEDIPOST CO., LTD.’s Japanese product, CATIS INC., and that earnings growth is gaining momentum.
Xcell Therapeutics Inc. is a company specializing in cell culture media, established in 2015. Culture media are raw materials for biopharmaceuticals that determine cell growth and function, and are used across the entire cell therapy and CDMO (Contract Development and Manufacturing Organization) industries. Cumulative revenue for the first half of the year reached approximately 3 billion won (up 438% year-over-year), while the operating loss totaled 5.6 billion won.
MEDIPOST CO., LTD., which recently successfully completed a Phase 3 clinical trial in Japan, has officially announced plans to switch to Excel Therapeutics’ chemically defined medium for its stem cell therapy “Cartistem,” used to treat knee osteoarthritis. This is significant as it marks the first instance of a bio-culture medium developed using proprietary domestic technology being applied to cell and gene therapies (CGTs) at the global commercialization stage. Stable revenue from the culture medium is expected to materialize alongside the commercialization of Cartistem, and growth in culture medium revenue is projected to accelerate if its application expands to MEDIPOST CO., LTD.’s additional pipeline products.